Paper Details

  1. Home
  2. Paper Details

Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives.

Author: AbadVivien C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Solriamfetol is a wake-promoting drug for treating excessive sleepiness (ES) associated with obstructive sleep apnea (OSA) or narcolepsy. It is a selective dopamine and norepinephrine reuptake inhibitor, demonstrating efficacy in reducing sleepiness and improving wakefulness. Solriamfetol is well tolerated and can be used as initial, replacement, or add-on therapy.
Paper Details　
Original Abstract of the Article :
Excessive sleepiness (ES) is a symptom of obstructive sleep apnea (OSA) and narcolepsy that has severe consequences. Wake-promoting drugs and stimulants are utilized as accessory treatment in OSA to reduce propensity to sleep but they do not improve sleep-disordered breathing. Solriamfetol is a firs...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846869/

データ提供：米国国立医学図書館（NLM）

Solriamfetol: A New Oasis for Combating Excessive Daytime Sleepiness

Excessive daytime sleepiness (ES) can feel like being trapped in a never-ending desert of fatigue, affecting both narcolepsy and obstructive sleep apnea (OSA). This article dives into the world of wake-promoting drugs, exploring the role of solriamfetol in combating ES. The study examines the effectiveness of solriamfetol in both narcolepsy and OSA, exploring its mechanism of action, efficacy, and tolerability.

Solriamfetol: A Beacon of Hope in the Desert of Sleepiness

The study found that solriamfetol effectively reduced sleepiness and improved wakefulness in both narcolepsy and OSA patients. This suggests that solriamfetol could offer a significant benefit for individuals struggling with these conditions, allowing them to feel more alert and engaged throughout the day. This is a promising development, like discovering a hidden oasis in the middle of a desert.

Seeking a Balanced Oasis: Navigating the Choice of Treatment

The article highlights the importance of careful patient selection when considering solriamfetol. It emphasizes that this medication is not a substitute for primary treatment for OSA and that it should be used alongside other therapies. It also discusses the potential for solriamfetol to be used as an initial therapy for patients who experience unacceptable side effects with other wake-promoting drugs, like finding the perfect balance for a long desert journey.

Dr. Camel's Conclusion

Solriamfetol offers a promising new option for individuals battling excessive daytime sleepiness. Its effectiveness in both narcolepsy and OSA, combined with its favorable tolerability profile, makes it a valuable tool for managing these conditions. Just as a camel relies on its unique adaptations to thrive in the desert, individuals with ES can now benefit from the potential of solriamfetol to help them regain control over their sleep and wakefulness.

Date :
  1. Date Completed n.d.
  2. Date Revised 2021-02-06
Further Info :

Pubmed ID

33531850

DOI: Digital Object Identifier

PMC7846869

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.